Revive Therapeutics Ltd. announced that it has filed a provisional patent application titled Compositions, methods and uses of Bucillamine in the treatment of a victim exposed to a chemical warfare agent. The methods and compositions described in the patent application relate to Bucillamine as a potential treatment of a victim exposed to the chemical warfare agent, including chemical warfare agents such as sulfur mustards, nitrogen mustards, nerve agents of G and V type, lewisite and adamsite. According to the U.S. Department of Homeland Security, a chemical attack is the spreading of toxic chemicals with the intent to do harm, which may include chemical weapons (warfare agents) developed for military use, toxic industrial and commercial chemicals that are produced, transported, and stored in the making of petroleum, textiles, plastics, fertilizers, paper, foods, pesticides, household cleaners, and other products, and chemical toxins of biological origin such as ricin.

The Company is commencing to work with advisors in developing a strategic plan to present its case in repurposing Bucillamine as a potential medical countermeasure for chemical warfare agent exposures to the Biomedical Advanced Research and Development Authority (BARDA), a part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. department of Health and Human Services. At this time, the Company will only provide regular updates via press releases as information becomes available.